#1 Clinical Trials Search in Europe

Explore popular drugs in clinical trials

Check which drugs are currently being frequently studied.

See also our rare diseases glossary and popular diseases list.

Starting by letter

To open the drugs glossary, select a letter from the list below.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All drugs

Most popular drugs

The list below features the most popular substances currently involved in ongoing clinical trials.

Drug Trials
Pembrolizumab 462
Sodium Chloride 431
Carboplatin 345
Cisplatin 287
Paclitaxel 263
Fluorouracil 238
Oxaliplatin 229
Nivolumab 217
Dexamethasone 211
Rituximab 200
Cyclophosphamide 191
Durvalumab 169
Bevacizumab 168
Paracetamol 160
Capecitabine 160
Atezolizumab 147
Docetaxel 133
Prednisone 129
Tocilizumab 126
Prednisolone 125
Mycophenolate Mofetil 122
Gemcitabine 122
Doxorubicin Hydrochloride 118
Venetoclax 118
Pemetrexed 117
Etoposide 116
Infliximab 102
Lenalidomide 102
Semaglutide 96
Acetylsalicylic Acid 94
Ipilimumab 92
Folinic Acid 90
Placebo 89
Paclitaxel Albumin-Bound 85
Calcium Folinate 83
Daratumumab 83
Fludarabine Phosphate 80
Methotrexate 79
Cytarabine 79
Letrozole 77
Dapagliflozin 76
Bortezomib 75
Gemcitabine Hydrochloride 73
Olaparib 72
Obinutuzumab 68
Azacitidine 67
Tacrolimus 67
Lenvatinib 67
Trastuzumab 66
Cetuximab 65
Fulvestrant 64
Irinotecan 63
Irinotecan Hydrochloride Trihydrate 62
Temozolomide 59
Methylprednisolone 59
Cemiplimab 57
Vincristine Sulfate 57
Trastuzumab Deruxtecan 53
Apixaban 53
Lidocaine Hydrochloride Monohydrate 52
Enzalutamide 52
Amoxicillin 51
Betamethasone Sodium Phosphate 50
Dexamethasone Sodium Phosphate 49
Codeine Phosphate 49
Ribociclib 49
Hydrocortisone 48
Exemestane 48
Lidocaine Hydrochloride 48
Buclizine Hydrochloride 47
Empagliflozin 47
Anastrozole 47
Adalimumab 47
Potassium Chloride 46
Clavulanic Acid 45
Pomalidomide 44
Tenofovir Alafenamide 44
Pertuzumab 44
Oxygen 44
Clopidogrel 43
Doxorubicin 43
Abemaciclib 43
Ibrutinib 43
Rivaroxaban 42
Ruxolitinib 42
Propofol 42
Cabozantinib 41
Cyclophosphamide Monohydrate 41
Trimethoprim 41
Sulfamethoxazole 41
Atorvastatin 41
Emtricitabine 40
Palbociclib 40
Ropivacaine Hydrochloride 40
Metformin Hydrochloride 40
Carfilzomib 40
Linezolid 39
Bendamustine Hydrochloride 39
Ifosfamide 38
Dostarlimab 38

New drugs in trials

The list below features the new substances involved to ongoing clinical trials.

#1 VMX-C001

Clinical trials are studying VMX-C001 in people who take a Factor Xa direct oral anticoagulant and need urgent surgery or another high-bleeding-risk procedure.

3 months ago
#2 LIPASE

Clinical trials are investigating LIPASE, including a new lipase product compared with pancrelipase.

3 months ago
#3 TRIACYLGLYCEROL LIPASE

Clinical trials of TRIACYLGLYCEROL LIPASE are studying a new lipase treatment in adults with exocrine pancreatic insufficiency.

3 months ago
#4 IMA401

Clinical trials are investigating IMA401 in patients with recurrent and/or refractory solid tumors.

3 months ago
#5 ALLERGEN EXTRACTS

Clinical trials are studying BLOMIA TROPICALIS POLYMERIZED EXTRACT as part of a vaccine for dust mite and Blomia tropicalis allergy.

3 months ago
#6 AUR200

Clinical trials are investigating AUR200 in people with generalized myasthenia gravis.

3 months ago

Drugs starting by s

  • 1 

    Sym023

    ,

    Sym023 is an innovative antibody being studied in clinical trials for the treatment of advanced solid tumors and lymphomas. This article explores the ongoing research into Sym023, its potential benefits, and its role in combination therapies for patients with difficult-to-treat cancers. We’ll examine the key findings from current clinical trials and what they mean for the future of cancer treatment.

    Related diseases and areas:

  • 1 

    Sym024

    ,

    A groundbreaking clinical trial is underway to investigate the potential of Sym024, an anti-CD73 antibody, in treating advanced solid tumor malignancies. This study aims to evaluate the safety and effectiveness of Sym024 both as a standalone treatment and in combination with Sym021, an anti-PD-1 antibody. The trial focuses on patients with metastatic cancer and solid tumors, offering hope for new treatment options in the fight against these challenging conditions.

    Related diseases and areas:

  • 2 

    Sym025

    , ,

    Sym025, also known as S095029, is an innovative anti-NKG2A antibody currently being studied in clinical trials for the treatment of advanced cancers. This article will provide an overview of the ongoing research involving Sym025, focusing on its potential applications in gastroesophageal junction/gastric cancer and non-small cell lung cancer (NSCLC). We’ll explore the objectives, eligibility criteria, and potential benefits of these trials, offering valuable insights for patients and healthcare professionals alike.

    Related diseases and areas:

  • 2 

    Syn2

    ,

    SYN2 is an innovative 18F-labelled tracer being studied in clinical trials for its potential in diagnosing coronary artery disease (CAD). These trials aim to evaluate the effectiveness of SYN2 in Positron Emission Tomography (PET) imaging for patients with suspected heart conditions. The studies focus on assessing the diagnostic performance, safety, and ability to quantify myocardial blood flow using SYN2 PET imaging.

    Related diseases and areas:

  • 1 

    Syn321

    ,

    A new drug called SYN321 is currently being studied in clinical trials for the treatment of knee osteoarthritis. This innovative medication is administered through intra-articular injections directly into the knee joint. The ongoing research aims to evaluate the safety, tolerability, and potential effectiveness of SYN321 in providing relief for patients suffering from this common and often debilitating condition.

    Related diseases and areas:

  • 7 

    Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues

    , , ,

    This article summarizes several clinical trials investigating the use of plozasiran, also known as ARO-APOC3, for treating hypertriglyceridemia. Plozasiran is a novel drug that targets apolipoprotein C-III mRNA to reduce triglyceride levels in the blood. The trials aim to evaluate the safety and efficacy of plozasiran in patients with varying degrees of hypertriglyceridemia, including severe cases and those with familial chylomicronemia syndrome.

    Related diseases and areas:

  • 1 

    Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Tmprss6 Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues

    ,

    This article discusses the clinical trials of SLN124, a novel drug being studied for the treatment of Polycythemia Vera (PV). SLN124 is a synthetic double-stranded siRNA oligonucleotide that targets TMPRSS6 mRNA and is linked to a ligand containing three N-acetylgalactosamine residues. The trials aim to assess the safety, efficacy, and potential benefits of SLN124 in managing PV symptoms and reducing the need for phlebotomies in patients with this condition.

    Related diseases and areas: